OR WAIT null SECS
April 24, 2020
MicrofluidX has raised £1.4 million (US$1.7 million) in seed funding, which it will use to develop its novel cell bioprocessing technology for cell and gene therapy.
A report into the Swiss biotech sector has shown that there is continued growth in the sector, which has received investments from public and private companies worth CHF 1.2 billion (US$1.2 billion).
April 23, 2020
The approval was based off of positive results from a Phase III study that showed patients 70 years or younger treated with the BTK inhibitor lived longer without disease progression.
April 22, 2020
US government and industry partners will coordinate to bring the most promising COVID-19 vaccine and treatment candidates to clinical trials.
The companies will collaborate on the discovery and development of next-generation drug and engineered cell therapies focused on natural killer cells.
April 21, 2020
The phase-II, randomized, double-blind, placebo-controlled trial will study the efficacy and safety of the live biotherapeutic in 90 individuals with COVID-19 symptoms.
April 16, 2020
Biopharmaceutical company, TScan Therapeutics, has entered into a collaboration agreement with Novartis that is aimed at the discovery and development of novel T-cell receptor (TCR) therapies for solid tumors.
This milestone achievement will allow the companies to move forward with developing a GMP-compliant manufacturing process for clinical testing.
April 15, 2020
Sanofi and GlaxoSmithKline (GSK) have revealed that they are joining forces to develop an adjuvanted vaccine using their respective technologies that can be used to fight COVID-19.
ISPE’s Facility of the Year Awards for 2020 go to bio/pharma companies in eight award categories, including two winners in the new Social Impact category.